Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Rosetta Capital is a UK-based venture capital firm with over 20 years of experience in the life sciences and medical device sectors. The firm has executed more than 50 transactions primarily in North America and Europe. Their investment strategy emphasizes direct secondary transactions and strategic engagement with portfolio companies.
Rosetta Capital invests in the life sciences and medical device sectors, focusing on seed, Series A, Series B, and growth equity stages. They provide flexible liquidity solutions through direct secondary transactions, supporting portfolio companies with follow-on financings and strategic management engagement.
Notable portfolio companies include Aprea Pharmaceutical - Exited, NovImmune - Exited, Inivata - Exited, Carrick Therapeutics - Public, Mission Therapeutics - Private, and Immunocore - Exited.
Email info@rosettacapital.com with your deck to pitch them.
Yes, Rosetta Capital often leads investment rounds, particularly in the life sciences sector, where they can provide strategic support and liquidity solutions.
Rosetta Capital actively supports follow-on investments to help their portfolio companies grow and achieve their strategic objectives.
Specific details about the size of Rosetta Capital's current fund are not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.